Data / Form D filings / ORAMED PHARMACEUTICALS INC.
ORAMED PHARMACEUTICALS INC.: Form D filings
ORAMED PHARMACEUTICALS INC., a pharmaceuticals company in Jerusalem, Israel, filed 9 Form D notices with the SEC between 2011 and 2014. The latest, on November 14, 2014, reports an offering of $5 million with nothing sold yet to 1 investor.
Find out what ORAMED PHARMACEUTICALS INC. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- HI-TECH PARK 2/4 GIVAT-RAM, Jerusalem, Israel, 91390
- Phone
- +972-2-566-0001
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1176309
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 14, 2014 | New notice | $5,000,000 | $0 | $5,000,000 | 1 | Yet to occur | sec.gov |
| Jan 3, 2013 | New notice | $474,500 | $31,500 | $443,000 | 1 | Mar 14, 2012 | sec.gov |
| Jan 2, 2013 | New notice | $76,360 | $76,360 | $0 | 1 | Dec 12, 2011 | sec.gov |
| Sep 27, 2012 | Amendment | $1,675,676 | $1,000,000 | $675,676 | 1 | Aug 28, 2012 | sec.gov |
| Sep 19, 2012 | Amendment | $1,675,676 | $1,000,000 | $675,676 | 1 | Aug 28, 2012 | sec.gov |
| Sep 12, 2012 | New notice | $1,675,676 | $1,000,000 | $675,676 | 1 | Aug 28, 2012 | sec.gov |
| Apr 13, 2011 | Amendment | $5,191,312 | $3,356,000 | $1,835,312 | 8 | Nov 18, 2010 | sec.gov |
| Feb 22, 2011 | Amendment | $4,665,375 | $3,016,000 | $1,649,375 | 6 | Nov 18, 2010 | sec.gov |
| Jan 18, 2011 | New notice | $5,000,000 | $2,350,000 | $2,650,000 | 3 | Nov 18, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Miriam Kidron | Executive Officer, Director | |
| Yifat Hen Zommer | Executive Officer | |
| Leonard Sank | Director | |
| Harold Jacob | Director | |
| Nadav Kidron | Executive Officer, Director | |
| Michael Berelowitz | Director | |
| Joshua Hen Hexter | Executive Officer | |
| Gerald M Ostrov | Director |
Every Form D from the week of Nov 10, 2014 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what ORAMED PHARMACEUTICALS INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.